UNH · UNITEDHEALTH GROUP INC

592 filings

UNH SEC Filings

UNITEDHEALTH GROUP INC - 592 total filings

Filing record · 2016–202610-K1110-Q328-K173

Showing 1–50 of 592 filings

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Oct 13, 2026)

UnitedHealth Group (UNH) reported third quarter 2026 results on October 13, 2026, with consolidated revenues of $112.7 billion (versus $113.2 billion a year earlier), earnings from operations of $6.6 billion (up from $4.3 billion), and a net margin of 3.6%. GAAP diluted EPS was $4.56 and adjusted EPS was $4.69, compared with $2.59 and $2.92 in the year-ago quarter. The improvement was driven primarily by a lower medical care ratio of 88.4% (versus 89.9%), which included $610 million of favorable prior-period reserve development, and an operating cost ratio that fell to 12.8% from 13.5%. Cash flow from operations was $5.1 billion, or 1.2x net income. Management raised its full-year 2026 outlook to at least $19.50 GAAP EPS and at least $20.50 adjusted EPS. Segment performance was mixed. UnitedHealthcare revenue declined to $86.3 billion, but operating margin improved to 3.3% from 2.1%, and membership fell to 48.3 million, with Medicare Advantage and Medicaid enrollment both contracting. Optum revenue fell to $66.9 billion, largely because Optum Health revenue dropped 10% as it exited markets lacking sufficient value-based care scale. Optum Health's earnings rebounded to $735 million from $41 million, Optum Insight grew revenue 3% to $5.5 billion, and Optum Rx earnings rose to $1.7 billion even as adjusted scripts declined to 393 million. Management also paired the results with a set of affordability, prior-authorization, and governance commitments, including a $1 billion United Health Foundation pledge. Investors should weigh the strong margin recovery against the shrinking membership base and the fact that part of the earnings lift came from favorable reserve development, which may not recur. Balance-sheet metrics show the company continuing to return capital while deleveraging only gradually. The debt-to-capital ratio rose to 41.7% from 41.2% in the prior quarter, above management's target of about 40.0% by year-end. Year-to-date, the company repurchased $5.0 billion of stock and paid $6.2 billion in dividends. Non-GAAP adjustments exclude intangible amortization, South American divestiture impacts, and certain restructuring items, so GAAP and adjusted figures should be reviewed together.

Oct 13, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Sep 8, 2026)

UnitedHealth Group Incorporated (UNH) has filed an 8-K report on September 8, 2026, primarily to announce upcoming participation in the Wells Fargo 21st Annual Healthcare Conference. Senior leadership will be available to discuss the company's strategy, market positions, recent performance, and outlook for its various end markets during an interview format at the conference on September 9, 2026. This provides investors with an opportunity for direct engagement and insight into the company's forward-looking perspectives. The company will also be providing a live audio webcast of the presentation, accessible via the Investor Relations section of its website. Investors should note that the information disclosed under Item 7.01 of this 8-K is not considered 'filed' for regulatory purposes under Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other SEC filings, unless specifically stated otherwise. This filing serves as a pre-announcement of management's participation and the topics to be covered.

Sep 8, 2026 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q2 Ended Jun 30, 2026

UnitedHealth Group's (UNH) Q2 2026 results demonstrate robust profitability growth, with net earnings attributable to common shareholders increasing by 61% year-over-year to $5.48 billion for the quarter, and 21% year-over-year to $11.76 billion for the six months ended June 30, 2026. This strong performance was driven by significant improvements in earnings from operations, which rose 55% to $8.0 billion in the quarter, primarily due to effective cost management and favorable medical cost trends, including a notable decrease in medical costs. The company experienced a shift in its business mix, with UnitedHealthcare's served population decreasing by 1.6 million, largely due to strategic benefit design and pricing actions, reduced Medicaid eligibility, and exiting certain states. Despite this decrease in volume, UnitedHealthcare's earnings from operations saw a substantial 90% increase, highlighting improved operational efficiency and profitability within the segment. Optum's performance was mixed, with Optum Health showing strong earnings growth driven by cost management and favorable reserve development, while Optum Rx revenue saw a slight decrease due to lower script volumes. Financially, UNH maintained a strong liquidity position, with cash flows from operating activities significantly increasing to $20.0 billion for the six months ended June 30, 2026. The company also demonstrated a commitment to returning capital to shareholders through a dividend increase and continued share repurchases. Despite regulatory pressures, particularly in Medicare Advantage, and ongoing medical cost trends, UnitedHealth Group has effectively navigated these challenges, delivering impressive financial results and demonstrating resilience in its diversified business segments.

Aug 10, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jul 16, 2026)

UnitedHealth Group (UNH) reported second quarter 2026 results on July 16, 2026, with revenues of $112.0 billion (up modestly from $111.6 billion a year earlier) and earnings from operations of $8.0 billion, versus $5.2 billion in Q2 2025. Diluted EPS was $6.04 and adjusted EPS was $6.38, compared with $3.74 and $4.08 a year earlier. The improvement was driven primarily by a medical care ratio of 86.7%, down from 89.4% a year ago, which benefited from pricing discipline, benefit design changes, favorable member mix, and $860 million of net favorable prior-period reserve development. Operating cost ratio rose to 12.7% from 12.3% as the company invested in technology, AI, care delivery, and community programs. Cash flow from operations was $11.1 billion, or 1.9x net income, though management attributed part of this to the timing of a substantial government payment. Management raised full-year 2026 guidance: diluted EPS is now expected at $18.45 to $18.95 and adjusted EPS at $19.50 to $20.00, up from $17.10 and $17.75 in January. The updated outlook assumes a full-year MCR of 88.1% (±25 bps), cash flows from operations of about $24 billion, and share repurchases of at least $5 billion. Segment trends were mixed: UnitedHealthcare membership fell to 48.5 million (down 525,000 sequentially) with Medicare Advantage seniors down 965,000 since year-end 2025, while UnitedHealthcare operating margin recovered to 4.6% from 2.4%. Optum earnings rose to $4.0 billion with a 6.2% margin, though Optum Health revenue fell 5% on roughly 700,000 fewer value-based-care patients. The filing also highlights a set of affordability and governance commitments, including prior-authorization reductions, a fee-based pharmacy model, a $1 billion commitment to the United Health Foundation, and ACA profit rebates. Investors should note that the guidance raise rests on a strong first half with a reserve release contributing to results, that membership continues to contract, and that the company's debt-to-capital ratio of 41.2% remains above its roughly 40% year-end target.

Jul 16, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Shareholder Vote Results (Jun 5, 2026)

UnitedHealth Group Inc. (UNH) filed an 8-K report detailing the outcomes of its 2026 Annual Meeting of Shareholders, held on June 1, 2026. The report indicates strong shareholder support for the company's leadership and financial oversight. All nine director nominees were overwhelmingly elected for one-year terms, reflecting confidence in the current board. Additionally, shareholders provided a non-binding advisory vote of approval for the company's executive compensation, with over 82% of the votes cast in favor. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was also overwhelmingly ratified, underscoring shareholder confidence in the company's financial reporting and auditing processes. A notable outcome was the rejection of a shareholder proposal requesting an independent board chair. This proposal received only approximately 20.24% of the votes cast, indicating that the majority of shareholders do not believe such a policy change is necessary at this time. Overall, the meeting results suggest a generally positive sentiment among UNH shareholders regarding the company's governance, executive compensation, and auditor selection.

Jun 5, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (May 11, 2026)

UnitedHealth Group Inc. (UNH) has filed a Current Report (8-K) on May 11, 2026, to announce that senior leaders will participate in an interview format at the Bank of America Securities Health Care Conference 2026 on May 12, 2026. The discussion will cover key aspects of the company's strategy, market positions, recent performance, and outlook for its end markets. This event provides investors with an opportunity to gain direct insights into management's perspective on the business and its future prospects. Investors are encouraged to tune into the live audio webcast, which will be accessible via the Investor Relations section of UnitedHealth Group's website. While this filing itself does not contain new financial data, it serves as a notification for an upcoming event where material information may be discussed. It is important to note that the information presented in this Item 7.01 is for disclosure purposes and is not considered 'filed' for regulatory purposes, unless expressly incorporated into future filings.

May 11, 2026 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q1 Ended Mar 31, 2026

UnitedHealth Group Inc. (UNH) reported its first quarter 2026 results, demonstrating steady revenue growth and robust earnings per share, though facing some membership contractions in key areas. Total revenues increased by 2% year-over-year to $111.7 billion, driven by price increases at UnitedHealthcare and growth at Optum Rx, offsetting declines in Medicare Advantage and Medicaid enrollment. Earnings from operations remained strong at $9.0 billion, with diluted earnings per share reaching $6.90, reflecting operational management and favorable reserve development despite increased operating costs. Significant strategic actions were undertaken, including portfolio divestitures and restructuring efforts, which resulted in net gains and impacts across segments like Optum Insight and Optum Health. While the company experienced a decline in the number of people served by UnitedHealthcare, particularly in Medicare Advantage and Medicaid, due to benefit design, pricing actions, and reduced eligibility, it also initiated forward share repurchase contracts and paid substantial dividends, indicating continued confidence and commitment to shareholder returns. The company is also actively pursuing pending acquisitions expected to close in the latter half of 2026.

May 5, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Apr 21, 2026)

UnitedHealth Group reported first quarter 2026 results that showed modest top-line growth and improved medical cost performance, while operating costs rose sharply. Total revenues were $111.7 billion, up 2% year over year, and earnings from operations were $9.0 billion, roughly flat versus $9.1 billion a year earlier. GAAP diluted EPS was $6.90 and adjusted EPS was $7.23, compared with $6.85 and $7.20 in the prior-year quarter. The medical care ratio improved 90 basis points to 83.9%, driven by cost management and favorable reserve development, but the operating cost ratio rose to 13.8% from 12.4% as the company invests in people, technology and AI. Management raised its full-year 2026 outlook to GAAP diluted EPS of greater than $17.35 and adjusted EPS of greater than $18.25. The company is also executing a portfolio refocus on U.S. health care, having completed the sale of Optum UK, with $400 million of proceeds committed to the United Health Foundation, and agreeing to acquire Alegeus Technologies, which is expected to close in the second half of 2026. It also plans to repurchase at least $2 billion of common stock by the end of Q2 2026 and expects its debt-to-capital ratio to reach about 40% in the second half of 2026, down from 42.9% at quarter end. The quarter also showed some pressure points. UnitedHealthcare membership fell, with Medicare Advantage seniors down 965,000 and Community & State people served down 220,000, and Optum Rx adjusted scripts declined to 383 million from 408 million. Optum Health revenue fell 3% as value-based care membership shrank. Investors will likely focus on whether the operating cost investments produce efficiency gains and whether membership attrition stabilizes.

Apr 21, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Mar 9, 2026)

UnitedHealth Group Inc. (UNH) has filed an 8-K report on March 9, 2026, primarily to announce upcoming participation in the Barclays 28th Annual Global Healthcare Conference. Senior leaders are scheduled to discuss the company's strategy, market positions, recent performance, and outlook for its end markets during an interview format on March 10, 2026. This provides an opportunity for investors to gain further insights into UNH's business and future expectations directly from its leadership.

Mar 9, 2026 10-K

UNITEDHEALTH GROUP INC Annual Report, Year Ended Dec 31, 2025

UNITEDHEALTH GROUP INC. (UNH) reported its 2025 fiscal year results, highlighting continued revenue growth across its segments, particularly in UnitedHealthcare and Optum Rx. Despite a strong top-line performance, the company's earnings from operations saw a significant decline of 41% compared to the prior year. This decrease was primarily attributed to elevated medical cost trends, which outpaced pricing assumptions, and the impact of restructuring and other actions totaling $2.5 billion. Key areas impacting profitability include increased medical costs driven by higher care activity, provider pricing, and the effects of the Inflation Reduction Act on Medicare Part D plans. UnitedHealthcare experienced a 16% revenue increase, driven by Medicare Advantage and fee-based commercial offerings, but its earnings from operations fell by 40% due to the aforementioned cost pressures and specific business adjustments. Optum, while growing revenues by 7%, saw its earnings from operations decrease by 43%, largely due to challenges within Optum Health, which reported a net loss from operations. This segment was impacted by Medicare Advantage funding reductions and medical cost trends. Optum Rx, however, demonstrated strong performance with a 16% revenue increase and a 23% rise in earnings from operations, benefiting from higher script volumes and a gain on a business deconsolidation. The company also managed its capital effectively, with significant cash flows from operations and a robust balance sheet, while continuing to return capital to shareholders through dividends and share repurchases.

Mar 2, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Mar 2, 2026)

UnitedHealth Group Inc. (UNH) has announced a key executive transition with the appointment of Dennis Stankiewicz as the new Chief Accounting Officer (CAO), effective March 2, 2026. Mr. Stankiewicz, who currently holds the position of Corporate Controller and joined UNH in 2016, brings extensive experience from his previous role as a partner at Deloitte & Touche, LLP, with over 24 years of professional background. This internal promotion signals continuity and leverages existing leadership within the company's financial operations. Concurrently, the outgoing CAO, Tom Roos, will move to the role of Chief Financial Officer for Optum Insight, UNH's health services platform. This strategic reshuffling of leadership roles underscores the company's commitment to experienced personnel in critical financial positions. The compensation package for Mr. Stankiewicz has been detailed, including a base salary, bonus targets, stock awards, and severance conditions, reflecting his new responsibilities. Investors should view this as a standard executive succession plan with no immediate implications for the company's operational or financial health, but rather a reinforcement of its established management structure.

Mar 2, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Feb 25, 2026)

UnitedHealth Group Inc. (UNH) has filed an 8-K detailing an amendment to a stock option grant for Stephen Hemsley, a key executive. The amendment introduces a new shareholding requirement, mandating that Mr. Hemsley retain any net shares acquired upon exercise of his May 14, 2025 stock option until May 14, 2030. This holding period follows an existing three-year cliff vesting schedule for the option.

Feb 25, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jan 27, 2026)

UnitedHealth Group reported full-year 2025 revenues of $447.6 billion (up 12% year-over-year), GAAP diluted EPS of $13.23 and adjusted EPS of $16.35, with earnings from operations of $19.0 billion. Fourth-quarter GAAP EPS was just $0.01 (adjusted $2.11), reflecting a $1.6 billion after-tax ($1.78 per share) charge covering final cyberattack costs, net portfolio divestitures, and restructuring. The adjusted medical care ratio rose to 88.9%, up 340 basis points year-over-year, driven by Medicare funding reductions, Inflation Reduction Act impacts, and elevated medical cost trends. UnitedHealthcare operating margin fell to 2.7% from 5.2%, while Optum Health swung to an operating loss of $278 million. For 2026, management guides to revenues above $439.0 billion (a roughly 2% decline), earnings from operations above $24.0 billion, GAAP EPS above $17.10, and adjusted EPS above $17.75. The outlook assumes a consolidated medical care ratio of 88.8% (plus or minus 50 basis points, a 30 basis point improvement), and an operating cost ratio of 12.8%. Revenue shrinkage is intentional, reflecting planned membership attrition of roughly 2.3 to 2.8 million people across medical products, Optum Rx client losses, and Optum Health right-sizing. Cash flow from operations is expected to exceed $18.0 billion, and the debt-to-capital ratio remains on a path toward 40% in 2026. Investors should weigh the meaningful improvement in guided margins and earnings against the still-elevated medical cost pressure and the significant reliance on repricing and membership shrinkage to deliver it. The results also include a substantial non-cash restructuring charge and ongoing reviews of business practices, which management says are still under way. Execution against the medical cost assumptions in 2026 will be the key test for the thesis.

Jan 27, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Jan 12, 2026)

UnitedHealth Group Inc. (UNH) has filed a Current Report (8-K) on January 12, 2026, primarily to disclose information regarding upcoming investor meetings on January 12, 2026. During these meetings, the company's senior management intends to reaffirm previously issued guidance for adjusted 2025 earnings per share (EPS), which was originally provided on October 28, 2025. It is crucial for investors to note that the company's financial closing procedures for the full year 2025 are not yet finalized. Consequently, actual reported results could differ from the reaffirmed expectations. This potential variance is attributed to ongoing financial closing procedures, final adjustments, management review, and other developments that may occur before the official finalization of the 2025 financial results.

Jan 12, 2026 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Nov 21, 2025)

UnitedHealth Group Inc. (UNH) has announced a significant addition to its Board of Directors with the appointment of Scott Gottlieb, M.D., as an independent director, effective immediately. Dr. Gottlieb brings a wealth of experience from his tenure as FDA Commissioner, where he focused on enhancing transparency, patient safety, and market competition, alongside initiatives in medical innovation and public health crises. His background also includes roles at CMS and a strong presence in health policy and investment. This appointment is noteworthy for investors given Dr. Gottlieb's recognized expertise in healthcare regulation, policy, and innovation. His insights are expected to be valuable as UNH navigates the complex and evolving healthcare landscape, potentially influencing strategic decisions related to regulatory affairs, market dynamics, and the adoption of new technologies. The company will compensate Dr. Gottlieb according to its standard director compensation program and has entered into an indemnification agreement.

Nov 21, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Bylaw Amendment (Nov 13, 2025)

UnitedHealth Group Inc. (UNH) filed an 8-K on November 12, 2025, to report a minor administrative change. The Company's Board of Directors approved an amendment to its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of this amendment was to update the registered office and registered agent of the Company in the State of Delaware. This filing does not contain any material financial updates or operational changes that would directly impact the company's performance or investor outlook.

Nov 13, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Nov 7, 2025)

UnitedHealth Group Inc. (UNH) has filed an 8-K report to disclose an upcoming investor event. Senior leadership will be participating in an interview at the UBS Global Healthcare Conference 2025 on November 10, 2025. This session is expected to cover the company's strategic initiatives, competitive positioning within its markets, recent financial performance, and outlook for its various business segments. Investors seeking forward-looking insights and a deeper understanding of UNH's operational strategy and market expectations should pay close attention to this conference. While this 8-K itself does not contain new financial data or material updates, it serves as a notification for a key opportunity to glean qualitative and potentially quantitative information directly from the company's leadership. The event will be accessible via a live audio webcast on the company's Investor Relations website, allowing for broad investor participation.

Nov 7, 2025 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q3 Ended Sep 30, 2025

UnitedHealth Group (UNH) reported its third-quarter 2025 results, showcasing robust revenue growth of 12% year-over-year to $113.2 billion, driven by strong performance across its UnitedHealthcare and Optum segments. Despite revenue expansion, the company experienced a significant decrease in earnings from operations, which fell 50% to $4.3 billion. This decline is attributed to a substantial increase in medical costs, up 21% to $80 billion, driven by higher care patterns, increased unit costs, and the impacts of the Inflation Reduction Act on Medicare Part D plans. The medical care ratio (MCR) consequently rose to 89.9% from 85.2% in the prior year. While the company continues to expand its reach, serving 795,000 more people primarily through Medicare Advantage, the pressure on medical costs and regulatory factors like Medicare Advantage funding reductions are impacting profitability. UnitedHealthcare's earnings from operations declined 57%, while Optum Health saw an 88% decrease, highlighting the challenges in managing health care costs within these segments. Conversely, Optum Insight and Optum Rx demonstrated resilience, with Optum Insight's earnings growing 46% and Optum Rx remaining stable, underscoring the diverse performance across UNH's business units. Investors should closely monitor the company's ability to manage medical cost trends and navigate the evolving regulatory landscape.

Oct 28, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Oct 28, 2025)

UnitedHealth Group (UNH) reported third quarter 2025 results on October 28, 2025, showing revenue growth alongside a sharp decline in profitability. Consolidated revenues rose 12% year-over-year to $113.2 billion, driven by UnitedHealthcare (up 16% to $87.1 billion, led by Medicare & Retirement) and Optum (up 8% to $69.2 billion, led by Optum Rx). However, earnings from operations fell 50% to $4.3 billion and net margin compressed to 2.1% from 6.0%. GAAP diluted EPS was $2.59 versus $6.51 a year earlier, and adjusted EPS was $2.92 versus $7.15. The medical care ratio rose 470 basis points to 89.9%, which management attributed to elevated medical cost trends, the effects of Biden-era Medicare funding reductions, and Inflation Reduction Act changes to the Part D program. Management said the MCR was in line with its second-quarter expectations and that medical reserve development was $80 million favorable. The key positive for investors is the raised full-year 2025 outlook: GAAP EPS of at least $14.90 and adjusted EPS of at least $16.25. Cash flow from operations was strong at $5.9 billion, or 2.3x net income. The debt-to-capital ratio held at 44.1%, including the Amedisys acquisition that closed on August 14, 2025. Management framed the quarter as part of a path to 'durable and accelerating growth in 2026 and beyond,' but the margin deterioration, especially at Optum Health (operating margin of about 1%), is the central issue for investors weighing the durability of the recovery. From a balance sheet and cash standpoint, total assets were $315.3 billion and equity was $101.6 billion at September 30, 2025. Nine-month operating cash flow was $18.6 billion, down from $21.8 billion a year earlier, while share repurchases ($5.5 billion) and dividends ($5.9 billion) were funded in part by net new borrowings of $2.4 billion. Optum Insight's contract backlog was stable at $32.1 billion, and membership growth continued, with UnitedHealthcare serving 50.1 million domestic consumers, up 795,000 year-over-year.

Oct 28, 2025 8-K

UNITEDHEALTH GROUP INC 8-K/A Report, Regulation FD Disclosure (Sep 9, 2025)

UnitedHealth Group (UNH) has issued an 8-K/A filing to update investors on upcoming meetings with analysts and investors. The company plans to reaffirm its adjusted 2025 earnings per share (EPS) expectations previously provided on July 29, 2025. Management acknowledged that the recently closed acquisition of Amedisys is expected to be dilutive to adjusted EPS in the near term due to financing costs and integration expenses. Additionally, UNH provided a preliminary outlook for its Medicare Advantage star ratings for Star Year 2026 / Payment Year 2027. Based on an initial review, the company anticipates approximately 78% of its membership will be in plans with 4 stars or higher, which is in line with their historical performance and expectations. These meetings will also cover broader topics like company strategy, market positions, and recent results, as previously disclosed.

Sep 9, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Sep 8, 2025)

UnitedHealth Group Inc. (UNH) has filed an 8-K to disclose information regarding upcoming investor and analyst meetings scheduled between September 8-10, 2025. The primary purpose of these meetings is to reaffirm the company's previously issued adjusted 2025 earnings per share (EPS) expectations from July 29, 2025. This reaffirmation is noteworthy as it incorporates the closing of the Amedisys acquisition in August 2025. Management anticipates that this acquisition will be modestly dilutive to adjusted EPS in the near term, primarily due to financing costs and integration-related investments. The meetings may also involve discussions around UnitedHealth Group's overarching strategy, its competitive market positions, and a review of recent financial results, all consistent with prior disclosures. Investors should note that the information provided is for informational purposes and should not be considered a filing for Section 18 of the Exchange Act, unless expressly incorporated into a future filing.

Sep 8, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Aug 20, 2025)

UnitedHealth Group Inc. (UNH) has announced significant changes to its Board of Directors structure, aimed at enhancing corporate governance and oversight. The company has established a new Public Responsibility Committee, which will focus on critical financial, regulatory, and reputational risks impacting its operations and mission. This committee's mandate includes overseeing underwriting, forecasting, regulatory relationships, reputational matters, and mergers and acquisitions, providing an additional layer of governance in these sensitive areas. Furthermore, the Board has appointed F. William McNabb as the new Lead Independent Director, succeeding Michele Hooper, who will continue her service and will chair the new Public Responsibility Committee. These changes reflect a commitment to a mission-driven culture and are designed to strengthen the company's ability to manage complex risks and maintain its integrity. Investors should view these governance enhancements positively, as they signal a proactive approach to risk management and board oversight.

Aug 20, 2025 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q2 Ended Jun 30, 2025

UnitedHealth Group (UNH) reported solid top-line growth in its second quarter of 2025, with total revenues increasing by 13% year-over-year to $111.6 billion. This growth was driven by a strong performance in UnitedHealthcare, particularly Medicare Advantage and commercial offerings, which saw a 17% revenue increase and a 1.03 million increase in people served. Optum's revenue also grew by 6%, primarily fueled by Optum Rx. Despite revenue growth, earnings from operations saw a significant decline of 35% to $5.2 billion, impacted by elevated medical cost trends, particularly within Medicare Advantage and the individual exchange offerings. This was further compounded by the ongoing effects of the Inflation Reduction Act (IRA) on Medicare Part D, and increased unit costs and care activity. The company continues to manage these pressures through cost management initiatives and strategic pricing adjustments.

Aug 11, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Jul 31, 2025)

On July 31, 2025, UnitedHealth Group (UNH) announced a leadership change in its finance function. Wayne S. DeVeydt, a former Elevance Health (formerly Anthem) CFO and current Bain Capital managing director, will become Chief Financial Officer effective September 2, 2025. John F. Rex, CFO since 2016, will transition to a Strategic Advisor role to CEO and Chairman Stephen J. Hemsley on the same date, under a 2016 employment contract. The filing's most investor-relevant content is DeVeydt's compensation package. It includes a $1,000,000 base salary, a 200% initial target bonus, a $10 million annual stock award target (pro-rated to $3 million for 2025), a $1.2 million cash sign-on bonus subject to clawback, and a $5 million sign-on stock award. Severance equals two times base salary plus the last two years' bonuses on termination without cause or for good reason. The filing does not disclose a reason for Rex's departure from the CFO role. For investors, the change is a planned transition with an overlap-free handoff date and an experienced health-insurance finance executive joining. DeVeydt's background at Anthem/Elevance, where he served as CFO for nine years, is directly relevant to managed care economics. The filing is a routine executive appointment disclosure and contains no reported financial results or guidance changes.

Jul 31, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jul 29, 2025)

UnitedHealth Group (UNH) reported second quarter 2025 results on July 29, 2025 and re-established its full-year 2025 outlook after suspending it on May 13, 2025. Q2 GAAP diluted EPS was $3.74 and adjusted EPS was $4.08, versus $6.80 adjusted a year earlier. Revenue rose to $111.6 billion (up about $12.8 billion year over year), but earnings from operations fell to $5.2 billion from $7.9 billion, and the consolidated medical care ratio rose 430 basis points to 89.4%. Management attributed the deterioration to medical cost trends that significantly outpaced pricing, including both unit costs and service intensity, along with the ongoing effects of Medicare funding reductions. The quarter also included $1.2 billion of unfavorable discrete items, including $620 million tied to the individual exchange business. The new 2025 outlook calls for revenue of $445.5 billion to $448.0 billion, GAAP diluted EPS of at least $14.65, and adjusted EPS of at least $16.00. The medical care ratio is guided to 89.25% (+/- 25 bps) and the operating cost ratio to 12.75%. Management expects a return to earnings growth in 2026, but its own disclosures indicate Medicare Advantage cost trend of roughly 7.5% in 2025 versus pricing of just over 5%, with 2026 pricing and benefit designs anticipating trend near 10%. Segment results were weak: UnitedHealthcare operating margin fell to 2.4% from 5.4%, and Optum Health earnings dropped to $636 million from $1.9 billion, with management acknowledging Optum's performance has not met expectations. Optum Insight and Optum Rx were comparatively stable. For investors, the key questions are whether the revised outlook adequately reflects elevated medical cost trends and whether the 2026 margin recovery thesis is credible given the trend assumptions described. Cash generation remained solid, with operating cash flow of $7.2 billion in Q2 (2.0x net income), and the company returned $4.5 billion to shareholders in the quarter, including a 5% dividend increase to $2.21 per quarter. The debt-to-capital ratio rose to 44.1%, which is worth monitoring alongside the lower earnings base.

Jul 29, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Corporate Update (Jul 24, 2025)

UnitedHealth Group (UNH) has disclosed in an 8-K filing dated July 23, 2025, that it proactively engaged with the Department of Justice (DOJ) following media reports concerning investigations into its Medicare program participation. The company has now commenced responding to formal criminal and civil requests from the DOJ. UNH asserts its full confidence in its business practices and is committed to a cooperative approach with the DOJ throughout this process. This development is significant for investors as it addresses potential regulatory scrutiny. UNH highlights its history of responsible conduct and strong compliance, referencing independent CMS audits that confirm the accuracy of its practices and a past court-appointed Special Master's conclusion in a decade-long civil challenge that found no evidence of wrongdoing. To further bolster transparency, the company is also conducting independent third-party reviews of its policies and practices related to risk assessment coding, managed care, and pharmacy services, as previously announced.

Jul 24, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Corporate Update (Jun 20, 2025)

UnitedHealth Group Inc. (UNH) has filed an 8-K report detailing the issuance of $3.5 billion in aggregate principal amount of senior notes. This debt offering comprises four tranches with varying interest rates and maturity dates, ranging from 2028 to 2055. The issuance was facilitated through an Underwriting Agreement and Pricing Agreement with a syndicate of major investment banks, including BofA Securities, Barclays Capital, Citigroup Global Markets, and J.P. Morgan Securities. This debt issuance diversifies UNH's capital structure and provides funds that can be utilized for general corporate purposes, potential acquisitions, or to refinance existing debt. Investors should note the different coupon rates and maturity profiles, which may appeal to a range of risk appetites and investment horizons. The registration of these notes under the Securities Act of 1933, via a Form S-3 shelf registration statement, indicates a routine capital markets transaction for a company of UNH's stature.

Jun 20, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Jun 4, 2025)

UnitedHealth Group Inc. (UNH) filed an 8-K on June 3, 2025, primarily detailing outcomes from its 2025 Annual Meeting of Shareholders held on June 2, 2025. A key executive change noted is the cancellation of performance-based restricted stock units previously granted to former CEO Andrew Witty in connection with his retirement. This action, agreed upon by Mr. Witty, removes potential future performance-based compensation tied to his tenure. The annual meeting itself saw shareholders re-elect all nine incumbent directors with substantial support, indicating continued confidence in the current board's leadership. Furthermore, shareholders provided a non-binding advisory vote of approval for the company's executive compensation. The appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2025 was also ratified with strong backing. Finally, a shareholder proposal seeking a vote on excessive 'golden parachute' compensation was voted down, suggesting shareholder consensus against further scrutinizing such arrangements at this time.

Jun 4, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (May 21, 2025)

UnitedHealth Group Inc. (UNH) has filed an 8-K announcing the immediate resignation of Andrew Witty from its Board of Directors, effective May 20, 2025. This departure means Mr. Witty will not be considered for re-election at the upcoming 2025 annual shareholder meeting scheduled for June 2, 2025. While the filing doesn't provide specific reasons for Mr. Witty's resignation, this change in board composition is a notable event for investors to monitor as the company moves forward.

May 21, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (May 14, 2025)

UnitedHealth Group (UNH) disclosed in this May 14, 2025 Form 8-K that CEO Andrew Witty stepped down effective May 12, 2025, and that the Board appointed Stephen J. Hemsley, a former CEO (2006-2017) who has been Board chair since 2017, as CEO. Hemsley remains Chair and stops receiving director compensation. Witty will serve as a senior advisor to Hemsley. The Board and Compensation Committee approved Hemsley's pay package: a $1,000,000 base salary, no annual cash incentive, a one-time $60 million nonqualified stock option grant with cliff vesting after three years, and no additional annual equity awards during his first three years. Severance is two times salary and bonus plus 24 months of option vesting, conditioned on a non-compete. The large one-time equity grant is a strong signal of the Board's intent to align Hemsley's incentives with a turnaround. The more consequential news for investors is the May 13, 2025 press release (Exhibit 99.1), which suspended the company's 2025 outlook. Management cited medical expenditures running higher than anticipated, as care activity accelerated and spread to more benefit types than in the first quarter, and medical costs for many Medicare Advantage beneficiaries new to UnitedHealthcare stayed elevated. The company said it expects a return to growth in 2026 and reiterated a long-term growth objective of 13% to 16%. Taken together, the filing reflects a sharp leadership change coinciding with a guidance withdrawal driven by medical cost pressure. Investors should weigh the reassurance of an experienced returning leader against the near-term uncertainty over earnings visibility, the sustainability of medical cost trends, and the timing of the expected 2026 recovery. The filing does not quantify the earnings impact of the suspended outlook, and the leadership details are incorporated by reference to the 2025 proxy statement.

May 14, 2025 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q1 Ended Mar 31, 2025

UnitedHealth Group reported strong first-quarter 2025 results, demonstrating significant revenue growth and improved profitability. Total revenues increased by 10% year-over-year, driven by robust performance in its UnitedHealthcare and Optum segments. The company successfully managed medical costs, with the medical care ratio improving slightly, indicating effective cost control measures despite increased care patterns. Earnings from operations saw a substantial increase of 15%, reflecting operational efficiencies and recovery from the prior year's cyberattack impact. The company also highlighted growth in the number of people served, particularly in Medicare Advantage and commercial offerings, underscoring its market leadership. UnitedHealth Group maintained a healthy cash flow from operations, providing ample liquidity for its ongoing operations, strategic investments, and capital return programs, including share repurchases and dividends. The company's strong financial position and operational execution position it well for continued growth.

May 7, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Apr 29, 2025)

UnitedHealth Group Inc. (UNH) announced a significant leadership transition within its Optum segment and enterprise-wide governance functions, effective May 6, 2025. Heather Cianfrocco, formerly the CEO of Optum, will now assume the critical role of Executive Vice President, Governance, Compliance and Information Security across the entire company. This move signals a strategic emphasis on strengthening oversight and security at the highest levels of the organization. Concurrently, Patrick Conway, M.D., who has been leading Optum Rx, has been appointed as the new Chief Executive Officer of Optum. Dr. Conway's prior experience within Optum, joining in February 2020, suggests a continuity of leadership and strategy within this key business segment. These appointments are presented by the company as part of its established leadership development process, aligning with its ongoing mission and strategic objectives.

Apr 29, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Apr 17, 2025)

UnitedHealth Group (UNH) reported first quarter 2025 results on April 17, 2025, with revenues of $109.6 billion (up $9.8 billion year-over-year), GAAP diluted EPS of $6.85 and adjusted EPS of $7.20. Earnings from operations rose to $9.1 billion from $7.9 billion, but the quarter's underlying margin picture was weaker than management had planned. The medical care ratio rose to 84.8% from 84.3%, driven by the ongoing Medicare funding reductions, a shift in member mix, and higher-than-expected senior care activity, particularly in Medicare Advantage physician and outpatient services. The more significant news for investors is the sharp cut to full-year 2025 guidance. Management lowered its GAAP EPS outlook to $24.65–$25.15 and its adjusted EPS outlook to $26.00–$26.50, both reflecting unexpected Medicare Advantage utilization and unanticipated changes in the Optum Health member profile tied to plan market exits. Management characterized these pressures as highly addressable during 2025 and reiterated a long-term earnings growth target of 13–16%, but the guidance reset signals that the company's cost trends and risk-adjusted economics were not tracking to expectations. Operating cash flow was strong at $5.5 billion, and the company returned nearly $5 billion to shareholders through dividends and buybacks. Return on equity was 26.8%. Segment results were mixed: UnitedHealthcare operating earnings rose to $5.2 billion with a 6.2% margin, while Optum earnings were $3.9 billion with a 6.1% margin. Optum Health revenue declined year-over-year to $25.3 billion, reflecting legacy contract revisions and member profile changes, while Optum Rx grew to $35.1 billion.

Apr 17, 2025 10-K

UNITEDHEALTH GROUP INC Annual Report, Year Ended Dec 31, 2024

UnitedHealth Group Inc. (UNH) presented a solid financial performance for the year ended December 31, 2024, marked by an 8% increase in total revenues to $400.3 billion. This growth was primarily driven by strong performance in its Optum segment, particularly Optum Rx and Optum Health, which saw revenue increases of 15% and 11% respectively, alongside a 6% rise in UnitedHealthcare's revenue. Despite a reported net loss of $7.98 billion on a diluted EPS basis (or $15.51 per share) due to a significant loss on the sale of its Brazil operations and other South American businesses ($8.3 billion), the company demonstrated operational resilience. Key operational highlights include serving a larger member base through UnitedHealthcare's domestic offerings, with a 5% increase in total individuals served. The company also managed the significant impact of the Change Healthcare cyberattack, incurring $2.2 billion in direct response costs and an estimated $867 million in business disruption impacts for Optum Insight, while providing over $9 billion in interest-free loans to care providers. Management remains focused on navigating medical cost trends, government funding pressures in Medicare Advantage, and ongoing investments in value-based care models and technology, positioning the company for continued strategic growth.

Feb 27, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jan 16, 2025)

UnitedHealth Group (UNH) reported fourth-quarter and full-year 2024 results on January 16, 2025 (Item 2.02 of the 8-K, with the press release furnished as Exhibit 99.1). Full-year revenues rose 8% year-over-year to $400.3 billion, driven by Optum Rx, Optum Health and UnitedHealthcare growth, and the company reaffirmed its 2025 outlook of $450–455 billion in revenue, $28.15–28.65 GAAP EPS and $29.50–30.00 adjusted EPS. Reported results were heavily distorted by one-time items: a $8.3 billion loss on the sale of its South American operations and about $2.2 billion of direct cyberattack response costs (plus $867 million of business disruption revenue reductions at Optum Insight). Reported full-year GAAP diluted EPS fell to $15.51 from $23.86, while adjusted EPS rose to $27.66 from $25.12. Investors should note that the adjusted figures exclude these items and that the full-year medical care ratio rose to 85.5% from 83.2%, reflecting Medicare funding reductions, member mix, Medicaid redeterminations and higher hospital coding intensity and specialty drug prescribing. Those cost pressures are embedded in the 2025 outlook. Cash flow from operations was $24.2 billion, or 1.6 times net income, and the company returned over $16 billion to shareholders through dividends and buybacks in 2024. Balance sheet leverage increased, with long-term debt rising to $72.4 billion from $58.3 billion, which partly funded acquisitions and cyberattack-related care provider loans. Fourth-quarter results were in line with the prior year on an adjusted basis, with no favorable prior-year medical reserve development, which makes the margin trajectory into 2025 the key focus for investors.

Jan 16, 2025 8-K

UNITEDHEALTH GROUP INC 8-K Report, Corporate Update (Dec 4, 2024)

UnitedHealth Group Incorporated (UNH) filed an 8-K on December 4, 2024, to announce a significant leadership change: the passing of Brian Thompson, Chief Executive Officer of UnitedHealthcare. This event, occurring on December 3, 2024, is communicated through an attached press release. While the filing itself is brief and primarily serves to disclose this important personnel news, investors should understand the implications of losing a key executive. The press release, incorporated by reference, likely contains further details about the circumstances of his passing and any immediate interim leadership plans. Investors will be looking for updates on business continuity and strategic direction following this unexpected event.

Dec 4, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Dec 3, 2024)

UnitedHealth Group issued updated 2024 financial guidance and initial 2025 projections ahead of its December 4, 2024 Investor Conference, disclosed under Item 7.01 (Regulation FD) with the full press release attached as Exhibit 99.1. The company projects 2025 revenues of $450 billion to $455 billion, GAAP diluted EPS of $28.15 to $28.65, adjusted EPS of $29.50 to $30.00, and cash flows from operations of $32 billion to $33 billion. For 2024, guidance calls for GAAP diluted EPS of $15.50 to $15.75 and adjusted EPS of $27.50 to $27.75. The large gap between the two years' GAAP figures reflects roughly $8.5 billion of South American impacts (including the loss on the Brazil sale and the held-for-sale classification of remaining South American operations) and about $2.0 billion of direct response costs related to the cyberattack, both of which are excluded from adjusted results. Investors should note that the 2025 GAAP EPS guidance is substantially higher because these 2024 charges are not expected to recur. On an adjusted basis, the midpoint of 2025 guidance ($29.75) implies roughly 7.7% growth over the 2024 midpoint ($27.63). The filing is a guidance update rather than a full earnings release, and it does not explain the drivers behind the 2025 projections. The forward-looking statements section lists a broad set of risks, including medical cost management, government program changes, DOJ litigation related to risk adjustment submissions, cyberattacks, and the continuing exit from South America. Investors should review the Investor Conference materials for management's commentary on these assumptions.

Dec 3, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Nov 26, 2024)

UnitedHealth Group Inc. (UNH) has announced its upcoming annual investor conference, scheduled to take place on Wednesday, December 4, 2024, in New York City. This event will provide an opportunity for analysts and institutional investors to hear directly from management, likely offering insights into the company's strategic priorities, financial performance outlook, and any significant operational updates. Investors should pay close attention to any forward-looking statements or guidance provided during the conference. The company will be live-streaming the presentations and management Q&A sessions, and conference materials will be made available on the Investor Relations section of their website. A replay will also be accessible online. This accessibility ensures that a broad range of investors can engage with the information presented, even if unable to attend in person.

Nov 26, 2024 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q3 Ended Sep 30, 2024

UnitedHealth Group (UNH) reported a solid third quarter with revenues reaching $100.82 billion, a 9% increase year-over-year, driven by strong performance in both the UnitedHealthcare and Optum segments. UnitedHealthcare saw a 7% revenue increase, primarily due to growth in Medicare Advantage and domestic commercial offerings, although this was partially offset by Medicaid redeterminations and Medicare funding pressures. The Optum segment delivered a robust 13% revenue growth, spearheaded by Optum Rx and Optum Health, demonstrating the company's diversified growth strategy. While net earnings attributable to common shareholders saw a decrease of 48% to $8.86 billion for the nine months ended September 30, 2024, largely influenced by a significant $7.1 billion loss from the sale of Brazil operations and a $1.2 billion loss from classifying remaining South American operations as held for sale, the company's operational performance remains resilient. The company also continues to navigate the ongoing impacts of the Change Healthcare cyberattack, incurring response costs and business disruption impacts, though mitigation efforts are progressing. UNH remains committed to returning capital to shareholders through dividends and share repurchases, with an increased quarterly dividend declared.

Nov 4, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Oct 15, 2024)

UnitedHealth Group reported third quarter 2024 results on October 15, 2024, with revenue of $100.8 billion, up $8.5 billion year over year, driven by growth in people served at Optum and UnitedHealthcare. GAAP diluted EPS was $6.51, and adjusted EPS was $7.15, which excludes $0.12 of Change Healthcare business disruption impacts and $0.28 of cyberattack direct response costs. Earnings were pressured by a higher medical care ratio of 85.2% (versus 82.3% a year earlier), which management attributed to Medicare funding reductions, medical reserve development effects, and business and member mix. The company recorded no favorable reserve development in the quarter. Full-year 2024 guidance was set at GAAP EPS of $15.50 to $15.75 and adjusted EPS of $27.50 to $27.75. Management said the adjusted range remains within the $27.50 to $28.00 range set about a year earlier, even after absorbing an estimated $0.75 per share of business disruption impacts from the Change Healthcare cyberattack, up roughly $0.10 from the prior estimate. The GAAP outlook reflects the first-half South America disposition activities, which produced a large loss for the nine months (a $8.3 billion loss on sale of subsidiary and subsidiaries held for sale). Cash flow and capital returns were solid. Third quarter operating cash flow was $14.0 billion, or 2.2 times net income, partly due to timing of cash receipts. Through the first nine months, the company returned over $9.6 billion to shareholders through dividends and share repurchases. Return on equity was 26.3%. Operating cost efficiency improved, with the operating cost ratio at 13.2% versus 15.0% a year earlier. Investors will likely focus on medical cost trends, reserve development, and the ongoing cyberattack costs, which the filing indicates are not yet fully resolved.

Oct 15, 2024 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q2 Ended Jun 30, 2024

UnitedHealth Group (UNH) reported strong revenue growth of 6% for the second quarter of 2024, reaching $98.9 billion, driven by robust performance in its OptumRx and Optum Health segments, as well as continued growth in UnitedHealthcare's domestic offerings. Despite the overall revenue increase, net earnings attributable to common shareholders declined by 23% to $4.2 billion, or $4.54 per diluted share. This decline was primarily due to a significant $1.2 billion loss recognized on the sale of South American operations and a substantial $8.3 billion loss related to the sale of its Brazil operations earlier in the year, alongside impacts from the Change Healthcare cyberattack. The company highlighted continued expansion in its UnitedHealthcare business, serving 1.6 million more people domestically, particularly in commercial offerings and Medicare Advantage. However, the Change Healthcare cyberattack led to direct response costs of $776 million and business disruption impacts of $334 million for the quarter, contributing to increased medical costs and a higher medical care ratio of 85.1%. Looking ahead, UNH is navigating pressures from Medicare Advantage rate reductions and evolving risk adjustment models, while also managing ongoing Medicaid redeterminations.

Aug 9, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Corporate Update (Jul 25, 2024)

UnitedHealth Group Inc. (UNH) has filed an 8-K report detailing a significant debt issuance that occurred on July 25, 2024. The company successfully sold a total of $11.45 billion in aggregate principal amount of senior notes across various maturities, ranging from 2026 to 2064. This substantial capital raise, executed through an underwriting agreement with a syndicate of prominent financial institutions, is being registered under the company's existing shelf registration statement. The specific terms, interest rates, and maturity dates for each tranche of notes have been disclosed, indicating a strategic move by UNH to bolster its financial resources or fund ongoing operations and investments. From an investor's perspective, this filing signifies UnitedHealth Group's proactive approach to managing its capital structure and ensuring financial flexibility. The issuance of long-term debt could be intended for various corporate purposes, including refinancing existing debt, funding strategic initiatives, acquisitions, or supporting its diverse healthcare service segments. Investors should note the variety of note maturities and coupon rates, which suggest a diversified approach to debt financing. While the filing doesn't explicitly state the use of proceeds, the scale of the issuance warrants attention regarding its potential impact on the company's leverage and overall financial strategy.

Jul 25, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jul 16, 2024)

UnitedHealth Group's Q2 2024 results (reported July 16, 2024) show revenue of $98.9 billion, up nearly $6 billion year over year, led by Optum and UnitedHealthcare. Reported GAAP diluted EPS was $4.54, down from $5.82 a year earlier, reflecting a $1.3 billion-plus pre-tax loss tied to the classification of the remaining South American operations as held for sale and cyberattack costs. Adjusted EPS was $6.80, up from $6.14, excluding South American impacts, direct cyberattack response costs, and intangible amortization, while including $0.28 per share of Change Healthcare business disruption impacts. Cash flow from operations was $6.7 billion for the quarter, or 1.5x net income. The company lowered its full-year 2024 GAAP EPS outlook to $15.95 to $16.40 (from prior guidance implied by the South America and cyberattack charges), but affirmed its adjusted EPS outlook of $27.50 to $28.00. Management expects total full-year cyberattack impacts of $1.90 to $2.05 per share, with direct response costs rising by $0.40 to $0.45 per share to support care providers and consumer notification, and business disruption impacts of $0.60 to $0.70 per share. The reported medical care ratio rose to 85.1% from 83.2%, driven by care provider accommodations, Medicare funding reductions, and mix, and no favorable reserve development was recognized in the quarter. For investors, the key questions are the durability of the cyberattack recovery and cost burden, the pace and proceeds of the South American exit, and whether medical cost trends stabilize. The quarter's growth in Optum Rx, Optum Health, and commercial domestic enrollment supports the core franchise, while the affirmed adjusted outlook signals management's confidence despite elevated one-time costs.

Jul 16, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Shareholder Vote Results (Jun 7, 2024)

UnitedHealth Group Inc. (UNH) filed an 8-K report detailing the outcomes of its 2024 Annual Meeting of Shareholders held on June 3, 2024. The meeting saw strong shareholder support for the election of all ten director nominees, with overwhelming 'For' votes for each individual. Additionally, shareholders provided a non-binding advisory approval of the company's executive compensation, indicating general satisfaction with the current compensation structure. The meeting also included a vote to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the upcoming fiscal year, which received substantial shareholder backing. However, a shareholder proposal requesting a report on political contributions' congruency was not approved by the majority of shareholders, signifying a lack of support for that specific initiative.

Jun 7, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (May 24, 2024)

UnitedHealth Group Inc. (UNH) has filed an 8-K report to disclose an upcoming participation in Bernstein's 40th Annual Strategic Decisions Conference. Senior leadership will be available to respond to investor questions in an interview format on Wednesday, May 29, 2024, starting at 8:00 a.m. Eastern Time. This event provides an opportunity for investors to gain direct insights into the company's strategic direction and operational performance. Investors are encouraged to listen to the live audio webcast, which will be accessible via the Investor Relations section of the UnitedHealth Group website. While this filing itself doesn't contain new financial results or material events, it serves as a notice for a future engagement where potentially market-moving information or commentary could be shared. The company emphasizes that the information presented in this 7.01 disclosure is not considered "filed" for regulatory purposes unless explicitly incorporated into future filings.

May 24, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (May 15, 2024)

UnitedHealth Group Inc. (UNH) has announced a significant change in its senior legal leadership. Effective June 4, 2024, Rupert Bondy, the current Executive Vice President, Chief Legal Officer, and Corporate Secretary, will transition to a new role as Senior Counsel and Executive Vice President, Governance, Compliance, and Security. This move signals a strategic shift in focus for Mr. Bondy towards governance and compliance areas within the company. Taking over the critical legal leadership positions will be Chris Zaetta, who currently serves as the Chief Legal Officer of Optum. Mr. Zaetta's appointment to Executive Vice President, Chief Legal Officer, and Corporate Secretary underscores his prominent role and expertise within the organization. Investors should monitor how this leadership transition impacts the company's legal strategy and ongoing regulatory matters.

May 15, 2024 10-Q

UNITEDHEALTH GROUP INC Quarterly Report for Q1 Ended Mar 31, 2024

UnitedHealth Group Inc. reported a net loss of $1.41 billion, or $(1.53) per diluted share, for the first quarter of 2024. This loss was significantly impacted by a $7.1 billion loss on the sale of its Brazil operations and the ongoing effects of the Change Healthcare cyberattack. Despite the net loss, total revenues increased by 9% year-over-year to $99.8 billion, driven by growth across both the UnitedHealthcare and Optum segments. UnitedHealthcare saw a 7% revenue increase, serving 1.6 million more people domestically, particularly in commercial and Medicare offerings. Optum revenues grew by 13%, fueled by Optum Health and Optum Rx. The company has provided substantial financial support to care providers affected by the cyberattack, totaling $3.9 billion in accelerated funding and interest-free loans by March 31, 2024, with further impacts anticipated. While the reported net loss is substantial, investors should note that it was heavily influenced by a one-time loss from divestiture and cyberattack-related costs. The underlying revenue growth indicates continued demand for the company's diverse health services. However, the cyberattack's ramifications, including potential litigation, reputational harm, and regulatory actions, remain significant uncertainties. Management is actively managing medical cost trends and operational efficiencies, but faces pressures from Medicare Advantage rate reductions and evolving risk adjustment models. The company maintains a strong liquidity position with substantial cash and investments.

May 9, 2024 8-K

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (May 9, 2024)

UnitedHealth Group Inc. (UNH) has filed an 8-K report to announce that senior leadership will participate in an interview at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. This event provides an opportunity for investors and analysts to hear directly from the company's executives regarding its business, strategy, and outlook within the healthcare sector. While no new financial results or material business updates are being disclosed in this specific 8-K filing, the conference participation signals ongoing engagement with the investment community.

May 9, 2024 8-K

UNITEDHEALTH GROUP INC 8-K/A Report, Cybersecurity Incident (Apr 24, 2024)

UnitedHealth Group filed Amendment No. 2 to its February 2024 Form 8-K, updating its Item 1.05 cybersecurity disclosure on the Change Healthcare cyberattack via a press release dated April 22, 2024 (Exhibit 99.1). The company said its preliminary, targeted data sampling has found files containing protected health information (PHI) or personally identifiable information (PII) that could cover a substantial proportion of people in America. It also stated it has not yet seen evidence of exfiltration of materials such as doctors' charts or full medical histories. Formal identification and notification of impacted individuals is expected to take several months, and the company is offering two years of free credit monitoring and identity theft protection through a call center that includes clinicians. Operationally, service restoration is well advanced. Pharmacy claims processing is back to near-normal levels, with 99% of pre-incident pharmacies able to process claims. Medical claims are flowing at near-normal levels, though a small number of providers remain adversely affected and are receiving alternative submission solutions and financial support. Change Healthcare payment processing, which handles about 6% of U.S. health care payments, was at roughly 86% of pre-incident levels, and approximately 80% of Change functionality has been restored on major platforms, with full restoration of other systems expected within weeks. For investors, the filing is primarily a disclosure update rather than a financial report: it contains no quantified financial impact, reserves, or guidance. The principal open risks are the scale of the data breach, the timing and cost of notifications and remediation, potential regulatory, legal, and litigation exposure, and whether restoration of remaining services is completed as projected. The company has also offered to handle notification obligations on behalf of providers and customers, which may increase its near-term administrative and financial burden.

Apr 24, 2024 8-K

UNITEDHEALTH GROUP INC 8-K/A Report, Executive Changes (Apr 17, 2024)

This 8-K/A filing from UnitedHealth Group Inc. (UNH) provides an amendment related to the compensation arrangements for Mr. Rex, a key executive. Specifically, it details the approval of his annual base salary, cash incentive award, and various stock-based awards by the Compensation and Human Resources Committee. These updates offer clarity on the remuneration structure for a senior member of the management team, which is a crucial aspect for investors to understand executive incentives and potential future share dilution. The approved compensation includes a base salary of $1,400,000, with a target annual cash incentive award of 200% of his base salary. Furthermore, Mr. Rex received significant stock awards, comprising stock options valued at $150,000, restricted stock units (RSUs) valued at $150,000, and performance shares valued at $300,000. These elements are designed to align executive compensation with company performance and shareholder value, providing insights into how the company retains and motivates its top talent.

Apr 17, 2024